Welgene Biotech Co.,Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 10, 2020 at 05:22 pm EST
Share
Welgene Biotech Co.,Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 98.977 million compared to TWD 126.585 million a year ago. Operating income was TWD 10.762 million compared to TWD 13.658 million a year ago. Net income was TWD 9.304 million compared to TWD 10.349 million a year ago. Basic earnings per share was TWD 0.45 compared to TWD 0.5 a year ago. For the nine months, sales was TWD 292.337 million compared to TWD 286.542 million a year ago. Operating income was TWD 26.580 million compared to TWD 23.783 million a year ago. Net income was TWD 20.438 million compared to TWD 18.242 million a year ago. Basic earnings per share was TWD 0.99 compared to TWD 0.88 a year ago. Diluted earnings per share was TWD 0.98 compared to TWD 0.88 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.
WELGENE BIOTECH CO.,LTD. 
